Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges
Viruses · 2025
DOI: 10.3390/v17010110 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Febri Gunawan Sugiokto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, PA 15219, USA. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Neoplasms, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institute of Allergy and Infectious Diseases R01.
Abstract (Originalsprache)
As a ubiquitous human pathogen, the Epstein–Barr virus (EBV) has established lifelong persistent infection in about 95% of the adult population. The EBV infection is associated with approximately 200,000 human cancer cases and 140,000 deaths per year. The presence of EBV in tumor cells provides a unique advantage in targeting the viral genome (also known as episome), to develop anti-cancer therapeutics. In this review, we summarize current strategies targeting the viral episome in cancer cells. We also highlight emerging technologies, such as clustered regularly interspersed short palindromic repeat (CRISPR)-based gene editing or activation, which offer promising avenues for selective targeting of the EBV episome for anti-cancer therapy. We discuss the challenges, limitations, and future perspectives associated with these strategies, including potential off-target effects, anti-cancer efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Program in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, PA 15219, USA.
- Cancer Virology Program, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.
- Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15219, USA.
ORCID-Profile: Febri Gunawan Sugiokto, Renfeng Li
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of Allergy and Infectious Diseases R01
- American Cancer Society Research Scholar
Zitieren
APA
Sugiokto, F. G., & Li, R. (2025). Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges. Viruses. https://doi.org/10.3390/v17010110
Vancouver
Sugiokto FG, Li R. Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges. Viruses. 2025. doi:10.3390/v17010110
BibTeX
@article{Sugiokto2025,
author = {Sugiokto, Febri Gunawan and Li, Renfeng},
title = {Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17010110}
}
EUVIMED